Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Potential of antibody–drug conjugates (ADCs) for cancer therapy
Hany E. Marei, Carlo Cenciarelli, Anwarul Hasan
Cancer Cell International (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 81

Showing 1-25 of 81 citing articles:

Optimizing the safety of antibody–drug conjugates for patients with solid tumours
Paolo Tarantino, Biagio Ricciuti, Shan M. Pradhan, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 8, pp. 558-576
Open Access | Times Cited: 119
Antibody–Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence
Pooja Gogia, Hamza Ashraf, S. Bhasin, et al.
Cancers (2023) Vol. 15, Iss. 15, pp. 3886-3886
Open Access | Times Cited: 86
A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy
Federico Riccardi, Michele Dal Bo, Paolo Macor, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 76
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study
Aditya Bardia, Ian E. Krop, Takahiro Kogawa, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 19, pp. 2281-2294
Open Access | Times Cited: 60
Mechanisms of Resistance to Antibody-Drug Conjugates
Rita Khoury, Khalil Saleh, Nadine Khalife, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9674-9674
Open Access | Times Cited: 58
The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress
Janet M. Sasso, Rumiana Tenchov, Robert E. Bird, et al.
Bioconjugate Chemistry (2023) Vol. 34, Iss. 11, pp. 1951-2000
Open Access | Times Cited: 55
Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response
Hannah L. Chang, Blake Schwettmann, Heather L. McArthur, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 18
Open Access | Times Cited: 42
CARBON DOTS: Bioimaging and Anticancer Drug Delivery
Michał Bartkowski, Yingru Zhou, Mustafa Nabil Amin Mustafa, et al.
Chemistry - A European Journal (2024) Vol. 30, Iss. 19
Open Access | Times Cited: 35
Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan
Rebecca S. Heist, Jacob Sands, Aditya Bardia, et al.
Cancer Treatment Reviews (2024) Vol. 125, pp. 102720-102720
Open Access | Times Cited: 16
Nanoparticle innovations in targeted cancer therapy: advancements in antibody–drug conjugates
Magdi T. Abdelhamid, Al-Hassan Soliman Wadan, Hosam A. Saad, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access | Times Cited: 4
Clinical translation of wireless soft robotic medical devices
Tianlu Wang, Yingdan Wu, Erdost Yıldız, et al.
Nature Reviews Bioengineering (2024) Vol. 2, Iss. 6, pp. 470-485
Closed Access | Times Cited: 15
Homogeneous multi-payload antibody–drug conjugates
Toby Journeaux, Gonçalo J. L. Bernardes
Nature Chemistry (2024) Vol. 16, Iss. 6, pp. 854-870
Closed Access | Times Cited: 13
Exploring Synergistic Interactions between Natural Compounds and Conventional Chemotherapeutic Drugs in Preclinical Models of Lung Cancer
Mihaela Boța, Lavinia Vlaia, Alex-Robert Jîjie, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 5, pp. 598-598
Open Access | Times Cited: 11
Self-reporting photodynamic nanobody conjugate for precise and sustainable large-volume tumor treatment
Yingchao Chen, Tao Xiong, Qiang Peng, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 11
Unleashing the Potential of Camptothecin: Exploring Innovative Strategies for Structural Modification and Therapeutic Advancements
Zheng Chen, Maoyu Liu, Ningyu Wang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 5, pp. 3244-3273
Closed Access | Times Cited: 9
Engineered Antibodies as Cancer Radiotheranostics
Zhen-Ni Wei, Bingyu Li, Xuejun Wen, et al.
Advanced Science (2024) Vol. 11, Iss. 30
Open Access | Times Cited: 9
Maytansinoids in cancer therapy: advancements in antibody–drug conjugates and nanotechnology-enhanced drug delivery systems
Matteo Perra, Ines Castangia, Matteo Aroffu, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Advancements in antibody-drug conjugates as cancer therapeutics
Jung Yin Fong, Zhixin Phuna, D. Chong, et al.
Journal of the National Cancer Center (2025)
Open Access | Times Cited: 1
T-Cell Engagers in Solid Cancers—Current Landscape and Future Directions
Mohamed Shanshal, Paolo F. Caimi, Alex A. Adjei, et al.
Cancers (2023) Vol. 15, Iss. 10, pp. 2824-2824
Open Access | Times Cited: 20
Drug Delivery Strategies for the Treatment of Pancreatic Cancer
Oluwabukunmi Olajubutu, Omotola D. Ogundipe, Amusa S. Adebayo, et al.
Pharmaceutics (2023) Vol. 15, Iss. 5, pp. 1318-1318
Open Access | Times Cited: 18
Advances in Targeted Therapy of Breast Cancer with Antibody-Drug Conjugate
Md Abdus Subhan, Vladimir P. Torchilin
Pharmaceutics (2023) Vol. 15, Iss. 4, pp. 1242-1242
Open Access | Times Cited: 17
Antibody-drug conjugates targeting HER2 for the treatment of urothelial carcinoma: potential therapies for HER2-positive urothelial carcinoma
Chia-Hsien Shih, Yu‐Hua Lin, Hao‐Lun Luo, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 8
When will the immune-stimulating antibody conjugates (ISACs) be transferred from bench to bedside?
Chen Fu, Weiwei Tong, Lifeng Yu, et al.
Pharmacological Research (2024) Vol. 203, pp. 107160-107160
Open Access | Times Cited: 8
Precision Medicine in Rheumatic Diseases: Unlocking the Potential of Antibody-Drug Conjugates
Zhiwen Huang, Zachary Braunstein, Jun Chen, et al.
Pharmacological Reviews (2024) Vol. 76, Iss. 4, pp. 579-598
Open Access | Times Cited: 6
Antibody-drug conjugates: the clinical development in gastric cancer
Yingze Zhu, Miao Zhou, Wenyue Kong, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top